Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma

According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (SOC) arm underwent both baseline and 12-month patient-reported outcome (PRO) assessments, capturing data before disease progression. Initial PRO compliance stood at 100%, showing a gradual decline in subsequent visits to 74% in the CARVYKTI arm and 81% in the SOC arm at the 12-month milestone. 

Throughout the analysis, patients in the CARVYKTI arm reported improved functioning and symptom reduction from baseline, while PRO scores in the standard of care (SOC) regimens, pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) arm trended toward worsening or lower degrees of improvement from baseline for most domains and symptoms.

KOL Insights

“These results from the CARTITUDE-4 study showed the potential of cilta-cel to significantly improve health-related quality of life measures for patients, including pain, fatigue, and emotional functioning. Cilta-cel has demonstrated deep and durable responses in later lines of therapy, and these results show the potential of cilta-cel for patients with lenalidomide-refractory multiple myeloma as early as after first relapse.”–Expert Opinion.

Conclusion

Ciltacabtagene autoleucel has exhibited profound and lasting responses in advanced treatment lines. These findings underscore the potential of cilta-cel for patients facing lenalidomide-refractory multiple myeloma, even as early as following the initial relapse.

Refer to the Related Reports for More In-depth Insights –